Literature DB >> 26658520

Molecules in medicine mini-review: isoforms of PI3K in biology and disease.

Bart Vanhaesebroeck1, Maria A Whitehead2, Roberto Piñeiro2.   

Abstract

The PI3K lipid kinases are involved in signal transduction and intracellular vesicular traffic, endowing these enzymes with multiple cellular functions and important roles in normal physiology and disease. In this mini-review, we aim to distill from the vast PI3K literature the key relevant concepts for successful targeting of this pathway in disease. Of the eight isoforms of PI3K, the class I PI3Ks have been implicated in the aetiology and maintenance of various diseases, most prominently cancer, overgrowth syndromes, inflammation and autoimmunity, with emerging potential roles in metabolic and cardiovascular disorders. The development of class I PI3K inhibitors, mainly for use in cancer and inflammation, is a very active area of drug development. In 2014, an inhibitor of the p110δ isoform of PI3K was approved for the treatment of specific human B cell malignancies. The key therapeutic indications of targeting each class I PI3K isoform are summarized and discussed.

Entities:  

Keywords:  Autoimmunity; Cancer; Diabetes; Immunity; Inflammation; Metabolic syndrome; Obesity; Overgrowth syndrome; PI3K; Pharmacological inhibitor; Signalling; Vesicular traffic

Mesh:

Substances:

Year:  2015        PMID: 26658520     DOI: 10.1007/s00109-015-1352-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  69 in total

1.  Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.

Authors:  Fabrizio Giordanetto; Andreas Wållberg; Saswati Ghosal; Tommy Iliefski; Johan Cassel; Zhong-Qing Yuan; Henrik von Wachenfeldt; Søren M Andersen; Tord Inghardt; Anders Tunek; Sven Nylander
Journal:  Bioorg Med Chem Lett       Date:  2012-09-06       Impact factor: 2.823

2.  Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.

Authors:  Kyle C Kurek; Valerie L Luks; Ugur M Ayturk; Ahmad I Alomari; Steven J Fishman; Samantha A Spencer; John B Mulliken; Margot E Bowen; Guilherme L Yamamoto; Harry P W Kozakewich; Matthew L Warman
Journal:  Am J Hum Genet       Date:  2012-05-31       Impact factor: 11.025

3.  P110delta, a novel phosphoinositide 3-kinase in leukocytes.

Authors:  B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

4.  PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.

Authors:  Fabienne Schmit; Tamara Utermark; Sen Zhang; Qi Wang; Thanh Von; Thomas M Roberts; Jean J Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-15       Impact factor: 11.205

Review 5.  Signalling by PI3K isoforms: insights from gene-targeted mice.

Authors:  Bart Vanhaesebroeck; Khaled Ali; Antonio Bilancio; Barbara Geering; Lazaros C Foukas
Journal:  Trends Biochem Sci       Date:  2005-04       Impact factor: 13.807

6.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

7.  Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.

Authors:  Inma M Berenjeno; Julie Guillermet-Guibert; Wayne Pearce; Alexander Gray; Stewart Fleming; Bart Vanhaesebroeck
Journal:  Biochem J       Date:  2012-02-15       Impact factor: 3.857

Review 8.  PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).

Authors:  Klaus Okkenhaug; Jan A Burger
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

9.  Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).

Authors:  John E Burke; Olga Perisic; Glenn R Masson; Oscar Vadas; Roger L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

10.  Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism.

Authors:  Lazaros C Foukas; Benoit Bilanges; Lucia Bettedi; Wayne Pearce; Khaled Ali; Sara Sancho; Dominic J Withers; Bart Vanhaesebroeck
Journal:  EMBO Mol Med       Date:  2013-03-11       Impact factor: 12.137

View more
  40 in total

Review 1.  PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling.

Authors:  Anne R Bresnick; Jonathan M Backer
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

2.  Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.

Authors:  Chengbin Yang; Xi Zhang; Yi Wang; Yongtai Yang; Xiaofeng Liu; Mingli Deng; Yu Jia; Yun Ling; Ling-Hua Meng; Yaming Zhou
Journal:  ACS Med Chem Lett       Date:  2017-07-26       Impact factor: 4.345

3.  PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression.

Authors:  Teresa Gagliano; Kalpit Shah; Sofia Gargani; Liyan Lao; Mansour Alsaleem; Jianing Chen; Vasileios Ntafis; Penghan Huang; Angeliki Ditsiou; Viviana Vella; Kritika Yadav; Kamila Bienkowska; Giulia Bresciani; Kai Kang; Leping Li; Philip Carter; Graeme Benstead-Hume; Timothy O'Hanlon; Michael Dean; Frances Mg Pearl; Soo-Chin Lee; Emad A Rakha; Andrew R Green; Dimitris L Kontoyiannis; Erwei Song; Justin Stebbing; Georgios Giamas
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 4.  Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF).

Authors:  Valentina Sala; Jean Piero Margaria; Alessandra Murabito; Fulvio Morello; Alessandra Ghigo; Emilio Hirsch
Journal:  Curr Heart Fail Rep       Date:  2017-06

5.  Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.

Authors:  Catherine A Evans; Tao Liu; André Lescarbeau; Somarajan J Nair; Louis Grenier; Johan A Pradeilles; Quentin Glenadel; Thomas Tibbitts; Ann M Rowley; Jonathan P DiNitto; Erin E Brophy; Erin L O'Hearn; Janid A Ali; David G Winkler; Stanley I Goldstein; Patrick O'Hearn; Christian M Martin; Jennifer G Hoyt; John R Soglia; Culver Cheung; Melissa M Pink; Jennifer L Proctor; Vito J Palombella; Martin R Tremblay; Alfredo C Castro
Journal:  ACS Med Chem Lett       Date:  2016-07-22       Impact factor: 4.345

6.  Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.

Authors:  Neeraj Jain; Satishkumar Singh; Georgios Laliotis; Amber Hart; Elizabeth Muhowski; Kristyna Kupcova; Tereza Chrbolkova; Tamer Khashab; Sayan Mullick Chowdhury; Anuvrat Sircar; Fazal Shirazi; Ram Kumar Singh; Lapo Alinari; Jiangjiang Zhu; Ondrej Havranek; Philip Tsichlis; Jennifer Woyach; Robert Baiocchi; Felipe Samaniego; Lalit Sehgal
Journal:  Blood Adv       Date:  2020-09-22

7.  Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth.

Authors:  Abul K Azad; Pavel Zhabyeyev; Bart Vanhaesebroeck; Gary Eitzen; Gavin Y Oudit; Ronald B Moore; Allan G Murray
Journal:  Oncogene       Date:  2020-09-02       Impact factor: 9.867

8.  Role of the PI3K/AKT pathway and PTEN in otitis media.

Authors:  Hwan Ho Lee; Anthony Chin; Kwang Pak; Stephen I Wasserman; Arwa Kurabi; Allen F Ryan
Journal:  Exp Cell Res       Date:  2019-12-13       Impact factor: 3.905

Review 9.  Defective phosphoinositide metabolism in autism.

Authors:  Christina Gross
Journal:  J Neurosci Res       Date:  2016-07-04       Impact factor: 4.164

10.  Translocation of TRPV4-PI3Kγ complexes to the plasma membrane drives myofibroblast transdifferentiation.

Authors:  Lisa M Grove; Maradumane L Mohan; Susamma Abraham; Rachel G Scheraga; Brian D Southern; James F Crish; Sathyamangla V Naga Prasad; Mitchell A Olman
Journal:  Sci Signal       Date:  2019-11-12       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.